down arrow

Qualigen Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74754R2022
USD
2.63
0.22 (9.13%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.352.66

52 Week

1.618.81
Valuation
Technical
Day's Volume

CASH

94.47 k

Shareholding (Sep 2024)

FII

0.08%

Held by 2 FIIs

DII

99.45%

Held by 0 DIIs

Promoter

0.00%

How big is Qualigen Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Qualigen Therapeutics, Inc. has a market capitalization of 2.58 million, with net sales of 0.00 million and a net profit of -7.77 million over the last four quarters. The company's shareholder's funds were -2.10 million, and total assets were 2.03 million as of Dec 23.

Market Cap: As of Jun 18, Qualigen Therapeutics, Inc. has a market capitalization of 2.58 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Qualigen Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -7.77 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company's shareholder's funds were -2.10 million, and total assets amounted to 2.03 million.

Read More

What does Qualigen Therapeutics, Inc. do?

22-Jun-2025

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing cancer and infectious disease treatments and its FastPack diagnostic platform. It has a market cap of $2.58 million and reported a net profit loss of $2 million as of September 2024.

Overview: <BR>Qualigen Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as the development of its FastPack diagnostic platform. The company operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap entity.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Sep 2024) <BR>Market-cap: USD 2.58 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.49 <BR>Return on Equity: 342.02% <BR>Price to Book: -1.21<BR><BR>Contact Details: <BR>Address: 1880 Century Park E Ste 1000, LOS ANGELES CA: 90067-1623 <BR>Tel: 1 310 2031000 <BR>Fax: 1 310 9191600 <BR>Website: https://www.qualigeninc.com/

Read More

Who are in the management team of Qualigen Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Qualigen Therapeutics, Inc. includes Michael Poirier (Chairman, CEO), Amy Broidrick (Executive VP, Chief Strategy Officer), and several independent directors: Ira Ritter, Richard David, Sidney Emery, Matthew Korenberg, and Kurt Kruger. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Qualigen Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Michael Poirier: Chairman of the Board, President, Chief Executive Officer<BR>- Ms. Amy Broidrick: Executive Vice President, Chief Strategy Officer, Director<BR>- Mr. Ira Ritter: Director<BR>- Mr. Richard David: Independent Director<BR>- Mr. Sidney Emery: Independent Director<BR>- Mr. Matthew Korenberg: Independent Director<BR>- Mr. Kurt Kruger: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Qualigen Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Qualigen Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5 and a price-to-book ratio of 1.8, indicating a solid balance sheet and favorable comparison to peers like Bio-Rad Laboratories and Thermo Fisher Scientific.

As of 15 October 2023, Qualigen Therapeutics, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid balance sheet and reasonable earnings relative to its market price.<BR><BR>In comparison to peers, Qualigen's valuation appears favorable against companies like Bio-Rad Laboratories, which has a price-to-earnings ratio of 25.4, and Thermo Fisher Scientific with a price-to-book ratio of 4.2. This suggests that Qualigen is trading at a discount relative to its more established counterparts. Additionally, the recent stock performance has outpaced the Sensex, further reinforcing the notion of its undervaluation.

Read More

Is Qualigen Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Qualigen Therapeutics, Inc. shows a mildly bearish trend overall, with mixed signals from various indicators, including mildly bullish weekly and monthly MACD, but a significant long-term decline of -67.38% over 1 year and -99.88% over 5 years compared to the S&P 500.

As of 29 August 2025, the technical trend for Qualigen Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are mildly bearish, and the Bollinger Bands reflect a mildly bearish trend in both weekly and monthly views. The KST presents a mixed picture with a bearish weekly signal and a mildly bullish monthly signal. Dow Theory indicates a mildly bullish weekly outlook but a bearish monthly stance. The OBV is mildly bullish weekly but mildly bearish monthly.<BR><BR>In terms of performance, the stock has shown a significant decline over the longer term, with a 1Y return of -67.38% compared to the S&P 500's 17.14%, and a staggering -99.88% over 5Y against the S&P 500's 96.61%. Overall, the current technical stance is mildly bearish, reflecting mixed signals across various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.99

stock-summary
Return on Equity

421.85%

stock-summary
Price to Book

-1.78

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
51.15%
0%
51.15%
6 Months
-32.39%
0%
-32.39%
1 Year
-41.92%
0%
-41.92%
2 Years
-92.79%
0%
-92.79%
3 Years
57.49%
0%
57.49%
4 Years
128.7%
0%
128.7%
5 Years
-99.85%
0%
-99.85%

Qualigen Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Qualigen Therapeutics, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Qualigen Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are mildly bearish, and the Bollinger Bands reflect a mildly bearish trend in both weekly and monthly views. The KST presents a mixed picture with a bearish weekly signal and a mildly bullish monthly signal. Dow Theory indicates a mildly bullish weekly outlook but a bearish monthly stance. The OBV is mildly bullish weekly but mildly bearish monthly. In terms of performance, the stock has shown a significant decline over the longer term, with a 1Y return of -67.38% compared to the S&P 500's 17.14%, and a staggering -99.88% over 5Y against the S&P 500's 96.61%. Overall, the current technical stance is mildly bearish, reflecting mixed signals across various in...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.90%
EBIT to Interest (avg)
-12.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
-1.23
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.75%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.29
EV to EBIT
-0.57
EV to EBITDA
-0.57
EV to Capital Employed
-3.48
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.47%)

Foreign Institutions

Held by 2 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 34.62% vs -188.89% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-2.70",
          "chgp": "37.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-2.60",
          "chgp": "34.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 50.40% vs 10.07% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.80",
          "val2": "-11.30",
          "chgp": "48.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "1.50",
          "chgp": "-40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-12.50",
          "chgp": "50.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.70
-2.70
37.04%
Interest
0.10
0.10
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-1.70
-2.60
34.62%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 34.62% vs -188.89% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.80
-11.30
48.67%
Interest
0.90
1.50
-40.00%
Exceptional Items
0.40
0.30
33.33%
Consolidate Net Profit
-6.20
-12.50
50.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 50.40% vs 10.07% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Qualigen Therapeutics, Inc. stock-summary
stock-summary
Qualigen Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.
Company Coordinates stock-summary
Company Details
1880 Century Park E Ste 1000 , LOS ANGELES CA : 90067-1623
stock-summary
Tel: 1 310 2031000
stock-summary
https://www.qualigeninc.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."